The European AIDS Conference, organised by the European AIDS Clinical Society (EACS) every two years, was formally linked this year with a new resistance and pharmacology workshop. Prior to the meeting the organisers also provided an intensive training programme for clinicians.

Reports in this issue of HTB include:

• Lower doses of d4T produce similar efficacy and reduced side effects

• Switching from efavirenz to nevirapine to avoid CNS side effects

• Interruption of treatment is safe for those who started too early

• T20 is cost effective for UK purchasers

• Intrauterine exposure to efavirenz

• African patients and adherence in the UK

• Five-year results of Kaletra-based therapy in treatment-naïve HIV patients

• IL-2 effectively increases CD4 count in people with low CD4 nadir

• Hepatitis coinfection: incidence in Europe and response to transplant

• Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)

Abstracts from the conference are available as a pdf file from the Aegis website:

http://www.aegis.org/conferences/eacs/

Other reports from this meeting are included on the following sites.

HIVandHepatitis.com
http://www.hivandhepatitis.com

The Body.com
http://www.thebody.com

NATAP
http://www.natap.org

Medscape (requires one-time free registration)
http://www.mescape.com